Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai's Abbisko Therapeutics Raises $28 Million for Cancer Drugs

publication date: Feb 7, 2017
Abbisko Therapeutics of Shanghai closed a $28 million A round to develop its preclinical portfolio of three oncology drug candidates. The company focuses on innovative small molecule immunomodulators for cancers prevalent in Asia, using a combination of in-house R&D and outside CROs. The investors were Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital. Abbisko, which is less than a year old, is located in Zhangjiang Hi-Tech Park, and is led by veteran pharma executives with experience in the west and China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital